Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
A phase 1/2 trial of STI-6129 in multiple myeloma, run by Zhejiang ACEA Pharmaceutical Co. Ltd., now recruiting.
Overview
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05565807 by Zhejiang ACEA Pharmaceutical Co. Ltd., with 84 participants planned, started 2023-02-09 and due to reach its primary completion in 2026-12-31. Interventions recorded: STI-6129. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Setting
A Phase Ib/IIa, Open-Label, Dose-Escalation and Extension Study to Evaluate the Safety and Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma
Phase
Phase 1/2
Sponsor
Zhejiang ACEA Pharmaceutical Co. Ltd.
Registry
Enrolled
84
Similar pages
not linked directly; found by shared links- TargetCD38
Shares STI-6129, Multiple myeloma.